Home › Research › TREM2 and immune genetics
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease
Wang L, Nykänen NP, Western D, Gorijala P, Timsina J, Li F, Wang Z, Ali M et al.. Molecular neurodegeneration, 2024-01-03
Topic: Brain proteins, microglia and lab models
Plain-language summary
Triggering receptor expressed on myeloid cells 2 (TREM2) plays a critical role in microglial activation, survival, and apoptosis, as well as in Alzheimer's disease (AD) pathogenesis. We previously reported the MS4A locus as a key modulator for soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF). To identify additional novel genetic modifiers of sTREM2, we performed the largest genome-wide association study (GWAS) and identified four loci for CSF sTREM2 in 3,350 individuals of European ancestry.
What this study adds
Evidence grade: Low
The record lists 3,350 participants. This genome-wide association study in 3,350 individuals identified four loci for cerebrospinal fluid sTREM2, including two independent missense variants in the MS4A locus. This is a genetic association study, so it does not show whether modifying these variants would treat, cure or prevent Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, L., Nykänen, N. P., Western, D., Gorijala, P., Timsina, J., Li, F., et al. (2024). Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease. Molecular neurodegeneration. https://doi.org/10.1186/s13024-023-00687-4
Vancouver
Wang L, Nykänen NP, Western D, Gorijala P, Timsina J, Li F, et al. Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease. Molecular neurodegeneration. 2024. doi:10.1186/s13024-023-00687-4. PMID: 38172904.
BibTeX
@article{wang2024-38172904,
author = {Wang, L. and Nykänen, N. P. and Western, D. and Gorijala, P. and Timsina, J. and Li, F. and Wang, Z. and Ali, M. and others},
title = {{Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease}},
journal = {Molecular neurodegeneration},
year = {2024},
doi = {10.1186/s13024-023-00687-4},
pmid = {38172904},
url = {https://doi.org/10.1186/s13024-023-00687-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We previously reported the MS4A locus as a key modulator for soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF).
- To identify additional novel genetic modifiers of sTREM2, we performed the largest genome-wide association study (GWAS) and identified four loci for CSF sTREM2 in 3,350 individuals of European ancestry.
- Through multi-ethnic fine mapping, we identified two independent missense variants (p.M178V in MS4A4A and p.A112T in MS4A6A) that drive the association in MS4A locus and showed an epistatic effect for sTREM2 levels and AD risk.
- The novel TREM2 locus on chr 6 contains two rare missense variants (rs75932628 p.R47H, P=7.16×10 -19 ; rs142232675 p.D87N, P=2.71×10 -10 ) associated with sTREM2 and AD risk.
Why it matters
This genome-wide association study in 3,350 individuals identified four loci for cerebrospinal fluid sTREM2, including two independent missense variants in the MS4A locus. This is a genetic association study, so it does not show whether modifying these variants would treat, cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Participants3,350
- Evidence strengthLow
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,350 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 56 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 7.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 3 / 4 | Cited 54 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Carlos C Cruchaga: h-index 102 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38172904) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-023-00687-4
- PubMed: 38172904
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 36.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.